ArticleThyroid : official journal of the American Thyroid Association2021
Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
Open access · greenAbstract read
In one paragraph
Article in Thyroid : official journal of the American Thyroid Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer.Cell death discovery · 2026Review
- Acetate Metabolism in Thyroid Cancer Progression.International journal of molecular sciences · 2026Article
- Integrative analysis of lysosome-dependent cell death related molecular subtypes and prognosis prediction in papillary thyroid carcinoma.Journal of Cancer · 2026Article
- Autophagy in thyroid cancer: stage-dependent switch, mutation-specific regulation, and therapeutic targeting.Oncology reviews · 2026Review
- The roles of both the endogenous synthesis and exogenous uptake of fatty acids in thyroid cancer cell proliferation.European journal of medical research · 2025Article
- Thyroid cancer: From molecular insights to therapy (Review).Oncology letters · 2025Review
- The Emerging Role of Mitochondrial Dysfunction in Thyroid Cancer: Mediating Tumor Progression, Drug Resistance, and Reshaping of the Immune Microenvironment.Biomolecules · 2025Review
- Short-Chain Polychlorinated Alkanes Exposure and Risk of Thyroid Cancer in a Population-Based Case-Control Study.Environment & health (Washington, D.C.) · 2025Article
- Reprogramming of fatty acid metabolism in thyroid cancer: Potential targets and mechanisms.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Reprogramming of Thyroid Cancer Metabolism: from Mechanism to Therapeutic Strategy.Molecular cancer · 2025Review
- Fatty acid metabolism influences the immune microenvironment in papillary thyroid cancer and identifies SCD as a novel biomarker.Frontiers in endocrinology · 2025Article
- Therapeutic implications of the metabolic changes associated with BRAF inhibition in melanoma.Cancer treatment reviews · 2024Review
- The Role of Lipid Metabolism Disorders in the Development of Thyroid Cancer.International journal of molecular sciences · 2024Review
- Article
- Low-Density Lipoprotein Receptor Is a Key Driver of Aggressiveness in Thyroid Tumor Cells.International journal of molecular sciences · 2023Article
- Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer.Metabolites · 2022Review
- ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer.Acta biochimica et biophysica Sinica · 2022Article
- Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?Cancers · 2022Article
- Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer.Oncogene · 2022Article
- Mitochondrial Respiration Inhibition Suppresses Papillary Thyroid CarcinomaFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Veronica ValvoLaboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Experimental Pathology, Department of Pathology, Cancer Research Institute (CRI), Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Asumi IesatoLaboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Experimental Pathology, Department of Pathology, Cancer Research Institute (CRI), Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Taylor R KavanaghDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Carmen PrioloDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Zsuzsanna ZsengellerDepartment of Pathology; Harvard Medical School, Boston, Massachusetts, USA.
Alfredo PontecorviDepartment of Medicine, Agostino Gemelli Medical School, UCSC, Rome, Italy.
Isaac E StillmanDepartment of Pathology; Harvard Medical School, Boston, Massachusetts, USA.
Suzanne D BurkeDepartment of Medicine; Harvard Medical School, Boston, Massachusetts, USA.
Xiaowen LiuDepartment of Emergency Medicine; Harvard Medical School, Boston, Massachusetts, USA.
Carmelo NuceraLaboratory of Human Thyroid Cancers Preclinical and Translational Research, Division of Experimental Pathology, Department of Pathology, Cancer Research Institute (CRI), Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Harvard University · USBeth Israel Deaconess Medical Center · USBrigham and Women's Hospital · USAgostino Gemelli University Polyclinic · ITBroad Institute · US
Funding
Role of newly identified, thyroid-specific LincRNA in BRAFV600E thyroid carcinomaR01CA248031 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NUCERA, CARMELO · 2020 to 2024
$2.0MBRAFV600E and VEGFR2 synergize to trigger papillary thyroid cancer progressionR01CA181183 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI NUCERA, CARMELO · 2014 to 2018
$1.8MNCI NIH HHS R01 CA181183NCI NIH HHS R01 CA248031
Abstract
PubMed holds no abstract for this paper.
Indexed as
MutationAcetyl-CoA CarboxylaseAnimalsAntineoplastic AgentsCell Line, TumorDatabases, GeneticDrug Resistance, NeoplasmEnergy MetabolismFatty AcidsGenetic Predisposition to DiseaseHumansLipogenesisMiceMitochondriaOxidation-ReductionPhenotypeACACB protein, humanAcetyl-CoA CarboxylaseAntineoplastic AgentsBRAF protein, humanFatty AcidsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafVemurafenibACC2beta-oxidationBRAFV600E, ACC1de novo lipid synthesisfatty acid synthesismitochondriaROSseahorsevemurafenib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.